SynderBio, Inc. is a startup founded on patented technology developed at the University of Iowa. The technology under development represents a new rapid and label-free approach to isolate and enrich malignant cancer cells from biological specimens in which there is a mixture of cancer and non-cancerous cells â something that is routinely done during cancer diagnosis and is especially vital for Next-Generation Sequencing. By enabling faster, less labor intensive processing of tumor biopsies and other specimens, SynderBioâs technology will benefit researchers, clinicians, pathologists, and patients. Faster, more consistent tissue preparation means lower and more predictable cost to pathology laboratory, and faster diagnosis and treatment for patien
